BACKGROUND: The association of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms with clinical presentation, biochemical measurements and response to therapies in acromegaly have been suggested. OBJECTIVE: To evaluate the presence of these polymorphisms in acromegaly and their influence on clinical and laboratorial characteristics of patients at diagnosis and after treatment in a large cohort of acromegalic patients. PATIENTS AND METHODS: This is a cross-sectional study developed in a single tertiary reference center. Clinical data were obtained from the medical records of 186 acromegalic patients (116 women, age range 21-88 years). GH and IGF1 levels and GHR-exon 3 and -202 A/C IGFBP3 polymorphisms were evaluated in the same hospital. RESULTS: At diagnosis, serum GH concentrations were lower in patients with GHR-d3 genotype than those with GHR-fl, whereas an association of lower IGFBP3 levels with d3 allele was observed only after neurosurgical or medical treatments. However, these associations were not confirmed in posterior statistical analysis. CONCLUSION: Our results suggest that GHR-exon 3 and -202 A/C IGFBP3 polymorphisms did not show any consistent association on clinical and laboratorial features of acromegalic patients even after treatment.
BACKGROUND: The association of GHR-exon 3 and -202 A/CIGFBP3 polymorphisms with clinical presentation, biochemical measurements and response to therapies in acromegaly have been suggested. OBJECTIVE: To evaluate the presence of these polymorphisms in acromegaly and their influence on clinical and laboratorial characteristics of patients at diagnosis and after treatment in a large cohort of acromegalicpatients. PATIENTS AND METHODS: This is a cross-sectional study developed in a single tertiary reference center. Clinical data were obtained from the medical records of 186 acromegalicpatients (116 women, age range 21-88 years). GH and IGF1 levels and GHR-exon 3 and -202 A/CIGFBP3 polymorphisms were evaluated in the same hospital. RESULTS: At diagnosis, serum GH concentrations were lower in patients with GHR-d3 genotype than those with GHR-fl, whereas an association of lower IGFBP3 levels with d3 allele was observed only after neurosurgical or medical treatments. However, these associations were not confirmed in posterior statistical analysis. CONCLUSION: Our results suggest that GHR-exon 3 and -202 A/CIGFBP3 polymorphisms did not show any consistent association on clinical and laboratorial features of acromegalicpatients even after treatment.
Authors: M Filopanti; L Olgiati; G Mantovani; S Corbetta; M Arosio; V Gasco; L De Marinis; C Martini; F Bogazzi; S Cannavò; A Colao; D Ferone; G Arnaldi; F Pigliaru; A Peri; G Angeletti; M L Jaffrain-Rea; A G Lania; A Spada Journal: J Clin Endocrinol Metab Date: 2011-12-07 Impact factor: 5.958
Authors: Laura Montefusco; Marcello Filopanti; Cristina L Ronchi; Luca Olgiati; Carmen La-Porta; Marco Losa; Paolo Epaminonda; Francesca Coletti; Paolo Beck-Peccoz; Anna Spada; Andrea G Lania; Maura Arosio Journal: Clin Endocrinol (Oxf) Date: 2010-05 Impact factor: 3.478
Authors: Antonio Bianchi; Gherardo Mazziotti; Laura Tilaro; Vincenzo Cimino; Flora Veltri; Eleonora Gaetani; Giovanni Pecorini; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Peter Kamenicky; Christine Dos Santos; Consuelo Espinosa; Sylvie Salenave; Françoise Galland; Yves Le Bouc; Patrick Maison; Pierre Bougnères; Philippe Chanson Journal: Eur J Endocrinol Date: 2009-05-13 Impact factor: 6.664
Authors: Ericka B Trarbach; Alexander A Jorge; Felipe H Duarte; Marcello D Bronstein; Raquel S Jallad Journal: Pituitary Date: 2017-06 Impact factor: 4.107
Authors: J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha Journal: J Endocrinol Invest Date: 2019-08-07 Impact factor: 4.256
Authors: Danny Ben-Avraham; Diddahally R Govindaraju; Temuri Budagov; Delphine Fradin; Peter Durda; Bing Liu; Sandy Ott; Danielle Gutman; Lital Sharvit; Robert Kaplan; Pierre Bougnères; Alex Reiner; Alan R Shuldiner; Pinchas Cohen; Nir Barzilai; Gil Atzmon Journal: Sci Adv Date: 2017-06-16 Impact factor: 14.136
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256